Sanofi (LON:0O59)
London flag London · Delayed Price · Currency is GBP · Price in EUR
79.82
+0.82 (1.04%)
At close: Feb 20, 2026
Market Cap83.91B -22.9%
Revenue (ttm)40.75B +5.5%
Net Income6.82B +40.5%
EPS5.56 +43.6%
Shares Outn/a
PE Ratio12.31
Forward PE9.54
Dividend3.30 (4.24%)
Ex-Dividend DateMay 12, 2025
Volume2,364,265
Average Volume1,972,232
Open80.47
Previous Close79.00
Day's Range79.02 - 80.50
52-Week Range75.76 - 110.84
Beta0.37
RSI49.44
Earnings DateJan 29, 2026

About Sanofi

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, COVID-19 vaccine Nuvaxovid, booster, meningitis, and travel and endemic vaccines, that in... [Read more]

Industry Pharmaceutical Preparations
Founded 1994
Employees 74,846
Stock Exchange London Stock Exchange
Ticker Symbol 0O59
Full Company Profile

Financial Performance

In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.

Financial numbers in EUR Financial Statements